Casdin Capital DGX Position
Active4-Fund ConvergenceCasdin Capital initiated a new position in QUEST DIAGNOSTICS INC (DGX) in Q4 2025, holding $8.7M worth of shares across 50,000 shares.
DGX is a convergence signal: 4 specialist biotech funds hold this stock, suggesting high institutional conviction.
About QUEST DIAGNOSTICS INC
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Full company profile →Short Interest
3.8%
4.9 days to cover
Frequently Asked Questions
Does Casdin Capital own DGX?
Yes. As of Q4 2025, Casdin Capital holds 50,000 shares of QUEST DIAGNOSTICS INC (DGX) valued at $8.7M. This data comes from their SEC 13F filing.
How many hedge funds own DGX?
4 specialist biotech hedge funds currently hold DGX, including RTW Investments, Redmile Group, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Casdin Capital first buy DGX?
Casdin Capital's position in DGX was first reported in Q4 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Casdin Capital's DGX position increasing or decreasing?
Casdin Capital initiated a new position in DGX in the most recent quarter. This is their first reported holding.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
DGXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Casdin CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →